HLB, HLB Life Science to Revive Merger; Group Restructures
Merger Fell Through Last Year After Appraisal Rights Claims Exceeded 40 Billion Won
"Consolidating Domestic Rights and Overseas Revenue Participation Rights to Rivoceranib"
Chairman Jin Yanggon to Step Down as CEO of HLB Innovation
HLB will absorb HLB Life Science through a merger. It is reviving a merger plan that fell through last year after a wave of shareholder claims for appraisal rights. The rights to rivoceranib, a new liver cancer drug, and the research staff are currently split between the two listed companies. HLB plans to bring them together under one company in preparation for commercialization. The HLB Group also carried out an organizational restructuring, creating a new future strategy unit and promoting a large number of executives in their 40s.
HLB and HLB Life Science said on the 19th that their respective boards had approved a plan for HLB to absorb HLB Life Science through a merger. HLB will issue new shares and distribute them to HLB Life Science shareholders. The merger price per share is 30,063 won for HLB and 2,578 won for HLB Life Science. Accordingly, each common share of HLB Life Science will be exchanged for 0.0857532 common shares of HLB. The two companies aim to complete the merger by June 30, 2027. After the merger, HLB, the surviving company, will remain listed on KOSDAQ and take over HLB Life Science's business, assets, liabilities, and contractual rights and obligations.
The merger's main objective is to consolidate the rights to rivoceranib. Rivoceranib is a targeted anticancer drug that HLB is developing as a treatment for liver cancer. HLB Life Science holds the exclusive rights to develop and sell the drug in South Korea, as well as the right to participate in revenue from the drug in Japan and Europe. In other words, the rights to the same drug were divided between the two companies by region. Once the merger is complete, the rights will be consolidated under HLB, allowing one company to make decisions on development and sales.
The companies will also combine their research and development organizations and existing businesses. HLB plans to absorb HLB Life Science's research staff and resources and assign them to developing its new drug pipeline. Medical consumables sold by HLB Life Science, including syringes, will also be sold through HLB's healthcare distribution network. The company said it could reduce costs by consolidating the management support organizations and internal transactions currently divided between the two companies.
The two companies pursued a merger for the same reasons last year but were unable to complete it. Shareholders opposing the merger demanded that the company buy their shares, and the total amount claimed for the shares exceeded 40 billion won, the termination threshold set out in the merger agreement. This time, the companies have strengthened their shareholder outreach. Each company formed a special committee comprising three independent directors and reviewed the fairness of the merger terms with advice from outside experts. They also plan to hold shareholder meetings and operate a Q&A channel on their websites.
The HLB Group also announced an organizational restructuring and executive appointments on the 19th. It established a Future Strategy Division and an AX Innovation Team within the Field Support Headquarters, a control tower directly under Chairman Jin Yanggon. The Future Strategy Division will develop mid- to long-term growth strategies, identify new businesses, and coordinate collaboration among affiliates. The AX Innovation Team will introduce artificial intelligence (AI) across management and establish a data-driven decision-making system. Son Dokuk was appointed head of the Future Strategy Division, and Kim Daeyong was appointed head of the Planning and Audit Division.
Chairman Jin will step down as CEO of HLB Innovation. Kim Beomsoo, president of HLB Innovation, has been named as his successor. Lee Wonjik, president, has been named as the next CEO of HLB Pep. The two are expected to be appointed following the regular shareholders' meetings and board meetings in March 2027. Afterward, HLB Innovation will be run by co-CEOs Kim Beomsoo and Brian Kim, while HLB Pep will be led by co-CEOs Lee Wonjik and Kim Jaeil. As chairman of the Group's board, Jin plans to focus on mid- to long-term growth strategies and securing new growth drivers.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Of the 22 executives promoted in this round of appointments, 11 are in their 40s. Three women were also promoted to executive positions: Jung Heeyoung, senior managing director of the Communications Team at the Group's Field Support Headquarters; Eom Hyuna, director of the Executive Support Team; and Shin Mirinae, director at HLB Pharmaceutical. Moon Junghwan, vice chairman of the HLB Group, said the appointments focused on placing next-generation leaders in key positions and strengthening the strategy and execution functions of the Group's control tower. He said the Group would sustain its growth through AI-driven management innovation and by securing future growth drivers.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.